Abstract Autonomic dysregulation is a feature of heart failure (HF) characterized by sustained increase of sympathetic drive and by withdrawal of parasympathetic activity. Both maladaptations are independent predictors of poor long-term outcome in patients with HF. Considerable evidence exists that supports the use of pharmacologic agents that partially inhibit sympathetic activity as an effective long-term therapy for patients with HF; the classic example being the use of selective and nonselective β-adrenergic receptor blockers. In contrast, modulation of parasympathetic activation as potential therapy for HF has received only limited attention. This review discusses the results of recent preclinical animal studies that provide support for the possible use of baroreflex electrical stimulation, also known as baroreflex activation therapy (BAT), as a long-term therapeutic approach for the treatment of patients with chronic HF. In addition to exploring the effects of chronic BAT on left ventricular (LV) function and chamber remodeling, the review will also address the effects of long-term BAT on ventricular arrhythmias and on potential modifiers of the HF state that include maladaptations of both the nitric oxide and β-adrenergic receptor signal transduction pathways. The results of the preclinical studies conducted to date have shown that in dogs with advanced HF, monotherapy with BAT improves global LV systolic and diastolic function and partially reverses LV remodeling both globally and at cellular and molecular levels. In addition, BAT therapy was shown to markedly increase the threshold for lethal ventricular arrhythmias in dogs with chronic HF. These benefits of BAT support the continued exploration of this therapeutic modality for treating patients with chronic HF and those with increased risk of sudden cardiac death.
Introduction
Autonomic dysfunction occurs in heart failure (HF) and is characterized by enhanced sympathetic activity and withdrawal of parasympathetic control. This autonomic imbalance has long been recognized as an important mediator of increased mortality and morbidity in myocardial infarction and HF [1, 2] . Results from the ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction Study) and the CIBIS II (Cardiac Insufficiency Bisoprolol Study II) showed that diminished vagal activity and increased heart rate (HR) are predictors of high mortality in these patient populations [3, 4] . The sustained increase of sympathetic drive along with reduced parasympathetic activity and activation of the renin-angiotensin-aldosterone system (RAAS) in HF also contribute to progressive left ventricular (LV) dysfunction, progressive LV remodeling, end-organ damage, and ultimately death [5] [6] [7] [8] [9] . The mechanisms responsible for sustained sympathetic excitation in HF are not fully understood. It is generally believed that the arterial reflexes, including the carotid sinus baroreflex, that are normally inhibitory to this system, have reduced sensitivity in HF and, therefore, allow sympathetic outflow to proceed unchecked [10] [11] [12] [13] [14] . Several studies have shown an abnormally depressed arterial baroreflex control in HF [11, 13, [15] [16] [17] [18] [19] [20] . This autonomic maladaptation in HF can lead to increased HR, dysregulation of key components of the cardiac β-adrenergic receptor signal transduction pathway, dysregulation of nitric oxide (NO) signaling, and the development of life-threatening ventricular arrhythmias.
Studies in conscious resting normal dogs have shown that activation of the carotid sinus reflex through electrical stimulation can decrease HR and can also decrease sympathetic constrictor tone during exercise [21] . Studies in patients have also shown that electrical stimulation of the carotid baroreflex can prolong the R-R interval secondary to augmented parasympathetic activity [22] . The modulation of HR and sympathetic tone are, at present, recognized as important therapeutic targets in HF. Chronic carotid sinus nerve stimulation has also been shown to be effective in the reversal of systemic arterial hypertension [23] relief of angina pectoris [24] , and improvement in HR variability [25•] and sympathetic inhibition [26•] . Numerous studies in experimental animal models of HF in which the long-term use of β blockers and other anti-adrenergic agents, and more recently from use of specific and selective agents that reduce HR through inhibition of the cardiac pacemaker current If, have shown that these agents can prevent or attenuate progressive LV remodeling [27] [28] [29] [30] .
While much of the emphasis in treating HF over the past two decades has focused on modulation of sympathetic activity, considerable interest has emerged recently in modulating parasympathetic activity as a therapeutic target for treating chronic HF. It has long been recognized that alteration in cardiac vagal efferent activity through peripheral cardiac nerve stimulation can produce bradycardia [31] , and modification in atrial [32, 33] ventricular contractile function [34, 35] . Electrical vagus nerve stimulation has been shown to prevent sudden cardiac death in conscious dogs with a healed myocardial infarction [36] and markedly improves long-term survival after chronic HF in rats [37, 38] . We recently showed that long-term electrical baroreflex activation therapy (BAT) in dogs with chronic HF can improve LV systolic function and attenuate progressive LV remodeling [39••] . The discussion that follows will focus on the beneficial consequences of restoring autonomic balance in HF through the use of long-term BAT delivered using the Rheos System (CVRx, Inc., Minneapolis, MN). We will show that the reduction in sympathetic overdrive and augmentation of parasympathetic drive with long-term BAT in animals with experimental HF can reduce HR, improve adrenergic receptor and NO signaling, and markedly increase the threshold for lethal ventricular arrhythmias and, in doing so, improve global LV function and partially reverse LV chamber remodeling. The latter has been shown to correlate well with improved long-term mortality and morbidity in patients with chronic HF.
BAT in Dogs with Coronary Microembolization-Induced HF
BAT Study Protocols in Dogs with MicroembolizationInduced HF Two separate studies were conducted in which the Rheos System was used to deliver BAT in dogs with microembolization-induced HF [40, 41] . In the first study dedicated primarily to hemodynamic and ventriculographic assessment of LV function and remodeling, 14 dogs with an LV ejection fraction of approximately 25 % were studied. Eight dogs were randomized to active BAT (Rheos System ON) and six to no therapy at all (sham-operated control, Rheos System OFF). All dogs were followed for 3 months. In the second study, dedicated primarily to electrophysiological (EP) testing for the induction of arrhythmias, 14 dogs also with LV ejection fraction about 25 % were studied. Seven dogs were randomized to active BAT (Rheos System ON) and seven to no therapy at all (sham-operated control, Rheos System OFF). In this study all dogs were followed for 6 months. In both studies, the Rheos System implant procedure and BAT stimulation were carried out as previously described [14, 40] . Briefly, stimulating electrodes were implanted circumferentially around both carotid sinuses and connected to the implantable pulse generator. Efficacy of the stimulation algorithm and proper placement of the electrodes were confirmed at the time of surgery by three to four acute stimulation runs performed 3 to 5 min apart and each confirming an acute drop of blood pressure and a reduction of HR. Dogs assigned to the BAT treatment group received a predetermined voltage with 0.5-msec square wave pulses at 50 to 100 Hz at a duty cycle of 9 min ON and 1 min OFF [39••] .
Effects of BAT on HR Assessed from Ambulatory Electrocardiogram Holter Monitoring
The effects of long-term treatment with BAT on HR and ventricular arrhythmias were evaluated in dogs with coronary microembolization-induced HF using 24-hour ambulatory electrocardiogram Holter monitoring [39••] . In sham-operated control dogs, maximum HR increased from 119±40 to 158±32 bpm, average HR increased from 69±22 to 76±15 bpm, and minimum HR increased from 39±11 to 45 ±11 bpm during a 3 month follow-up period. In BAT-treated dogs, maximum HR decreased from 161±40 to 122±47 bpm, average HR decreased from 92±19 to 64±18 bpm, and minimum HR decreased from 54±18 to 38±11 bpm [39••] . Even though none of these HR changes reached statistical significance, the trends support the premise that BAT reduces HR in the setting of HF [ The increase in ejection fraction was associated with an increase of both stroke volume and cardiac output,suggesting a clear improvement of LV systolic function. Long-term treatment with BAT also improved indexes of LV diastolic function as evidenced by a significant increase in early mitral inflow deceleration time, a decrease of LV enddiastolic pressure, an increase in the ratio between peak mitral flow velocity in early diastole to peak mitral inflow velocity during left atrial contraction, and a decrease in LV end-diastolic circumferential wall stress ( Fig. 1 ) [39••] . The change in these diastolic indexes with BAT supports the premise that BAT may also improve LV diastolic function in addition to improving LV systolic function. Long-term treatment with BAT significantly decreased LV end-systolic and end-diastolic volumes suggesting that this form of therapy can have a beneficial effect on reducing LV size (Fig. 1) . BAT also improved indices of LV shape [39••] and significantly reduced functional mitral regurgitation [37] . The reduction in LV size, the restoration of ellipsoidal LV shape, and the reduction in the severity of functional mitral regurgitation suggest that this form of chronic therapy can reverse, albeit partially, the structural changes that drive pathologic LV remodeling.
Effects of BAT on Cellular Measures of LV Remodeling
In dogs with coronary microembolization-induced HF, long-term treatment with BAT elicits important changes in cellular and structural markers of LV remodeling. Histomorphometric assessment performed at the end of 3 months of follow-up showed that compared to control, treatment with BAT resulted in nearly 40 % reduction in the volume fraction of replacement fibrosis [39••] . This observation suggests that ongoing cardiomyocyte loss and thus their replacement by fibrous tissue may be prevented or attenuated when long-term therapy with BAT is implemented. Treatment with BAT was also associated with a near 22 % reduction in reactive interstitial fibrosis, a finding that can lead to improved LV relaxation and LV compliance and thus LV filling. HF is also accompanied by a reduction in myocardial capillary to fiber ratio and by an increase in the oxygen diffusion distance (half the distance between two adjoining capillaries) that can lead to hypoxia of the failing myocardium [42] . Studies in dogs with HF showed that long-term treatment with BAT is associated with near normalization of capillary density and a near 16 % reduction in oxygen diffusion distance [42] . Finally, long-term treatment with BAT was associated with a near 24 % reduction in cardiomyocyte cross-sectional area, a measure of cardiomyocyte hypertrophy [42] . These data suggest that BAT can attenuate pathologic hypertrophy and in doing so, restore a near-normal LV mass that is in line with available blood supply. In dogs with coronary microembolization-induced chronic HF, long-term treatment with BAT resulted in partial normalization of components of the cardiac β-adrenergic signaling pathway (Fig. 2) [39••] . Compared to LV myocardium of sham-operated control dogs, the LV myocardium of dogs treated with BAT showed upregulation of mRNA expression of β1-adrenergic receptors with no change in the expression of β2-adrenergic receptors. BAT-treated dogs also showed upregulation of mRNA expression of adenylyl cyclase and downregulation of β-adrenergic receptor kinase. These improvements at the molecular level were accompanied by a significant reduction in circulating plasma norepinephrine levels [39••] . Longterm treatment with BAT also resulted in downregulation of angiotensinogen, leading to a possible partial deactivation of the vasoconstrictive influence of tissue RAAS [39••] . These findings suggest that delivery of BAT in dogs with HF may restore sensitivity of the failing myocardium to adrenergic stimulation while attenuating the detrimental action of RAAS-induced vasoconstriction.
Effects of BAT on Isoforms of NO Synthase
The effects of long-term treatment with BAT on the nitric oxide synthases (NOS) were also examined in dogs with microembolization-induced HF [38] . NO is formed from the guanidine group of L-arginine in an NADPH-dependent reaction catalyzed by a family of NOS enzymes namely, endothelin NOS (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS). It is well known that NO produced by eNOS plays an important role in the regulation of cell growth, programmed cell death, and vasodilation [43] . NO produced from eNOS from cardiomyocytes can enhance myocardial relaxation and regulate contractility as well as coronary perfusion [44, 45] . In dogs with coronary microembolization-induced HF, mRNA and protein expression of eNOS in LV myocardium is significantly downregulated compared to normal dogs [46] . Long-term treatment with BAT significantly improves mRNA expression of eNOS (Fig. 2) 
iNOS is expressed by many different cell types including cardiomyocytes and is upregulated in HF [45] . Increased expression of iNOS can lead to apoptosis [47] and can result in peroxynitrite generation associated with fibrosis, LV hypertrophy, chamber dilation, and a cardiomyopathic phenotype [48] . Increased expression of iNOS has also been shown to be associated with increased incidence of heart block and of sudden cardiac death [48] . In dogs with coronary microembolization-induced HF, mRNA and protein expression of iNOS in LV myocardium is significantly upregulated compared to normal dogs [46] . Long-term treatment with BAT has been shown to normalize mRNA expression of iNOS in the failing dog LV myocardium (Fig. 2) [39••] .
Recent studies have suggested that nNOS is present in cardiomyocytes [49] and may be associated with the ryanodine receptor calcium release channel in the sarcoplasmic reticulum [50] and, therefore, may act to influence calcium cycling and contractility [50] . nNOS is upregulated in myocardium of rats with myocardial infarctions and in human failing hearts [51] . In rats with HF, preferential inhibition of nNOS leads to increased sensitivity of the myocardium to β-adrenergic stimulation; a finding consistent with the concept that nNOS-derived NO production may play a role in the autocrine regulation of myocardial contractility [52] . In dogs with coronary microembolization-induced HF, mRNA and protein expression of nNOS in LV myocardium is significantly upregulated compared to normal dogs [46] . Long-term treatment with BAT was shown to normalize mRNA expression of iNOS in the failing dog LV myocardium (Fig. 2) 
The observation of normal physiologic balance between NOS isoforms suggests that increased elaboration of NO occurs following treatment with BAT. It is difficult to directly assess the level of NO due to its very short half-life in the body. Measurements of the levels of NO metabolites, specifically the pool of nitrate and nitrite, are often used as a reflection of changes in levels of NO. In the failing LV myocardium, the level of these metabolites of NO is significantly lower than in normal myocardium. Long-term treatment with BAT in dogs with HF increase in the total pool of nitrate and nitrite in LV myocardium, thus supporting the concept that restoration of autonomic balance in HF elicits normalization of physiologic NO synthesis and elaboration.
Effects of BAT on Outcomes of EP Testing
A characteristic of patients with HF is the high incidence of malignant ventricular arrhythmias that frequently culminate in sudden cardiac death. Patients with HF in whom these lethal arrhythmias can be induced by EP testing carry a high risk of sudden cardiac death. The effect of long-term treatment with BAT on EP-induced ventricular arrhythmias was also evaluated in dogs with microembolization-induced HF described earlier. EP testing was conducted at baseline prior to therapy and after 3 and 6 months of treatment with BAT (n 07) or no treatment at all (control, n 07). Programmed ventricular stimulation was performed from the right ventricular apex and included delivery of up to four extrastimuli at progressively shorter coupling intervals (in steps of 10 msec). The extrastimuli were delivered following eight ventricular-paced beats with a drive cycle length between 600 and 200 msec. If a sustained monomorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) could not be induced, then isoproterenol infusion was initiated to increase the sinus rate by about 30 % and the EP stimulation protocol was repeated ( Fig. 3) [53] . At baseline, a sustained VT or VF was induced in all 14 dogs (100 %). After 3 and 6 months of follow-up, all control dogs (100 %) were induced into sustained VT or VF. After 3 months of BAT, only 3 of 7 dogs (43 %) were induced into sustained VT or VF. After 6 months of BAT, only 2 of 7 dogs (29 %) were induced into sustained VT or VF (Fig. 3) . In addition to these findings, the arrhythmia resistance index-a measure of the severity of stimulation needed to elicit VT or VF-was significantly higher in BATtreated dogs at 3 months and at 6 months compared to controls. Finally, 6 weeks after withdrawal of BAT (stimulation OFF) all seven dogs assigned to the BAT group (100 %) were again induced into sustained VT or VF and the arrhythmia resistance index was returned to levels seen before initiating BAT (Fig. 3) . These results suggest that monotherapy with BAT markedly increases the threshold for lethal ventricular arrhythmias in dogs with chronic HF. This benefit of BAT supports the continued exploration of this device as a therapeutic modality for treating patients with chronic HF and increased risk of sudden cardiac death.
BAT in Dogs with Rapid Pacing-Induced HF
The long-term effects of treatment with BAT were also examined in dogs with pacing-induced HF [14] . BAT electrode implantation was similar to that described earlier for dogs with microembolization-induced HF. Of a total 15 dogs studied, 7 received BAT and 8 were assigned to control and did not receive BAT. Treatment with BAT was initiated 2 weeks after initiation of right ventricular pacing at 250 bpm and all animals were followed for up to 12 weeks. In this study, there was no difference in LV ejection fraction or LV fractional area of shortening between treated dogs and controls. Treatment with BAT, however, significantly lowered LV end-diastolic pressure. In addition, survival was significantly greater for dogs undergoing BAT compared to control dogs (68.1± 7.4 vs 37.3±0.2 days) [14] . This improvement in survival in BAT-treated dogs was associated with significantly lower plasma levels of plasma norepinephrine and angiotensin II [14] . It was speculated that the beneficial effects of BAT on survival in this animal model of HF may have been due, in part, to favorable modulation of sympathetic overdrive and excess activation of the RAAS [14] .
Conclusions and Clinical Implications
A considerable body of preclinical and clinical investigations exists that supports the benefits of reducing sympathetic drive and enhancing parasympathetic drive in the management of patients with HF. β-Blockers as well as other drugs that selectively lower HR such as ivabradine, an inhibitor of the If current, are examples of pharmacologic interventions that favorably modulate sympathetic and parasympathetic drive in patients with HF and, in doing so, improve long-term outcome. In recent years, we have experienced an emergence of devices that also target autonomic imbalance in HF. These include electrical cervical vagus nerve stimulators, spinal cord stimulators, and electrical baroreflex activators as described in this review. In animals with experimental HF, long-term BAT improves LV systolic and diastolic function and partially reverses LV remodeling. BAT normalizes mRNA expression of key components of the β-adrenergic signal transduction pathway. Reversal of this maladaptive gene expression is likely to restore sensitivity of the failing myocardium to catecholamines and explains, in part, the improvement of LV function seen following chronic BAT. BAT also normalizes mRNA expression of eNOS, nNOS, and iNOS in LV myocardium of dogs with HF. This finding provides additional insights into the possible mechanisms of action of this form of therapy. In addition to improving LV function, long-term monotherapy with BAT markedly increases the threshold for lethal ventricular arrhythmias in dogs with chronic HF and prolongs survival in dogs with pacing-induced HF. These benefits of BAT strongly support the continued exploration of this therapeutic modality for the treatment of patients with chronic HF and increased risk of sudden cardiac death. Fig. 3 a, Recording in an untreated control dog during an electrophysiological study showing the induction of a monomorphic VT (upper tracing) associated with hemodynamic compromise depicted by fall in systemic arterial pressure (lower tracing) and requiring direct current (DC) cardioversion. b, Recording in a BAT-treated dog during an electrophysiological study showing the induction of VF (upper tracing) associated with hemodynamic compromise depicted by fall in systemic arterial pressure (lower tracing) and requiring DC cardioversion. c, Bar graphs (mean) depicting the proportion of dogs in whom a VT or VF was induced at pretreatment (Pre), 3 months (3 M), and 6 months (6 M) after initiating BAT treatment or no treatment and at 6 weeks (6 W) after withdrawal of BAT treatment (6 W starting at the end of 6 M of active treatment, Post). d, Bar graphs (mean±SEM) depicting changes in the arrhythmias resistance index, a measure of the severity of the arrhythmia-inducing protocol (least severe being S1 600 and most severe being ISO+IP), in control dogs and dogs treated with BAT. BAT-baroreflex activation therapy; BP-burst pacing; IPincremental pacing; ISO-isoproterenol; VF-ventricular fibrillation; VT-ventricular tachycardia Clinical trials employing the recently introduced, secondgeneration CVRx Barostim neo (CVRx, Inc.) are currently underway to evaluate the safety and efficacy of BAT therapy for the treatment of patients with HF.
